CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today reported financial results for the year ended December 31, 2016.
Mark Perrin, InVivo’s CEO and Chairman, said, “2016 was a year marked by meaningful and significant progress. In 2016, we:
received approval for converting the Neuro-Spinal Scaffold™ pilot study to the pivotal INSPIRE study;
received approval to initiate the INSPIRE study in Canada (1st global step for InVivo);
added 13 new clinical sites, including our first ex-U.S. sites (both in Canada);
enrolled seven new patients, with three of those patients achieving the primary endpoint of conversion to partial paralysis by six months post-injury1;
continued our spinal cord injury (SCI) thought leadership by attending and presenting at international conferences, where we presented 13 scientific abstracts to renowned leaders within the neurosurgical, neuroscience, and SCI communities;
raised $32 million (gross), which is the company’s largest fund raising to date;
successfully developed a preclinical prototype of the TrailMaker™ for the chronic spinal cord injury market and filed two patent applications;
garnered unique media coverage about InVivo and the Neuro-Spinal Scaffold in 18 widely-read outlets resulting in nearly 30 million media impressions;
and continued to make great strides in strengthening our research and intellectual property portfolio.
